PT2001855E - Derivados de benzimidazol e respectiva utilização para modular o complexo receptor gabaa - Google Patents
Derivados de benzimidazol e respectiva utilização para modular o complexo receptor gabaa Download PDFInfo
- Publication number
- PT2001855E PT2001855E PT07727240T PT07727240T PT2001855E PT 2001855 E PT2001855 E PT 2001855E PT 07727240 T PT07727240 T PT 07727240T PT 07727240 T PT07727240 T PT 07727240T PT 2001855 E PT2001855 E PT 2001855E
- Authority
- PT
- Portugal
- Prior art keywords
- disorder
- compound
- receptor complex
- agoraphobia
- disease
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title claims description 7
- 108091008681 GABAA receptors Proteins 0.000 title claims description 7
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title claims description 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 2
- 150000001556 benzimidazoles Chemical class 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- YUXCRCCATFXYCX-UHFFFAOYSA-N 2-[1-[3-(2-fluoropyridin-3-yl)phenyl]benzimidazol-5-yl]propan-2-ol Chemical compound C1=NC2=CC(C(C)(O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1F YUXCRCCATFXYCX-UHFFFAOYSA-N 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 201000002426 animal phobia Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical class C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- -1 sedation Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78527806P | 2006-03-24 | 2006-03-24 | |
| DKPA200600426 | 2006-03-24 | ||
| DKPA200601327 | 2006-10-12 | ||
| US85128406P | 2006-10-13 | 2006-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2001855E true PT2001855E (pt) | 2011-01-17 |
Family
ID=39456294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07727240T PT2001855E (pt) | 2006-03-24 | 2007-03-22 | Derivados de benzimidazol e respectiva utilização para modular o complexo receptor gabaa |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7902230B2 (enExample) |
| EP (2) | EP2319837B1 (enExample) |
| JP (1) | JP5260489B2 (enExample) |
| KR (1) | KR20080111097A (enExample) |
| CN (1) | CN101384559B (enExample) |
| AR (1) | AR060084A1 (enExample) |
| AT (1) | ATE486856T1 (enExample) |
| AU (1) | AU2007229502B2 (enExample) |
| BR (1) | BRPI0710203A2 (enExample) |
| CA (1) | CA2647252A1 (enExample) |
| CY (1) | CY1111603T1 (enExample) |
| DE (1) | DE602007010261D1 (enExample) |
| DK (1) | DK2001855T3 (enExample) |
| ES (1) | ES2355163T3 (enExample) |
| HR (1) | HRP20100616T1 (enExample) |
| IL (1) | IL192297A (enExample) |
| MX (1) | MX2008010885A (enExample) |
| MY (1) | MY149855A (enExample) |
| NO (1) | NO20084481L (enExample) |
| NZ (1) | NZ569438A (enExample) |
| PL (1) | PL2001855T3 (enExample) |
| PT (1) | PT2001855E (enExample) |
| RU (1) | RU2435759C2 (enExample) |
| SI (1) | SI2001855T1 (enExample) |
| TW (1) | TWI391381B (enExample) |
| WO (1) | WO2007110374A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604516A1 (en) | 2005-04-13 | 2006-10-19 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| US7923464B2 (en) | 2005-12-05 | 2011-04-12 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
| TWI391381B (zh) * | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| AU2008345696A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Benzimidazole compounds |
| WO2010055129A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| TW201029987A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| WO2010055130A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| WO2010055133A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| TW201029986A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| TW201029989A (en) * | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
| WO2014053409A1 (en) * | 2012-10-01 | 2014-04-10 | F. Hoffmann-La Roche Ag | Benzimidazol.es as cns active agents |
| CN107445845A (zh) * | 2017-08-24 | 2017-12-08 | 重庆沃肯精细化工有限公司 | 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法 |
| US12139508B2 (en) * | 2018-02-11 | 2024-11-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| HUE060943T2 (hu) * | 2018-09-13 | 2023-04-28 | Saniona As | A gaba A receptor ligandum |
| KR102219563B1 (ko) * | 2019-02-15 | 2021-02-24 | 에스티팜 주식회사 | 페나진 유도체 제조를 위한 중간체 및 그의 제조방법 |
| CA3155618A1 (en) * | 2019-10-23 | 2021-04-29 | Jed Hubbs | Treatment of epileptic conditions with gabaa receptor modulators |
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| CN116693555B (zh) * | 2022-02-25 | 2025-07-04 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| AU2024411621A1 (en) | 2023-12-27 | 2026-06-18 | Saniona A/S | A gabaa receptor ligand and the use thereof in medicine, in particular in the treatment of epilepsy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK40192D0 (da) | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| ES2150671T3 (es) * | 1995-04-21 | 2000-12-01 | Neurosearch As | Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a. |
| CA2218493C (en) * | 1995-04-21 | 2005-02-22 | Neurosearch A/S | Benzimidazole compounds and their use as modulators of the gabaa receptor complex |
| AU726447B2 (en) * | 1996-10-21 | 2000-11-09 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators |
| CN1275127A (zh) | 1997-10-10 | 2000-11-29 | 神经研究公司 | 苯并咪唑化合物、含该化合物的药物组合物及其应用 |
| BR0011823A (pt) * | 1999-06-22 | 2002-03-19 | Neurosearch As | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo |
| US7335777B2 (en) | 2003-04-03 | 2008-02-26 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
| MXPA05010449A (es) * | 2003-04-03 | 2006-05-31 | Neurosearch As | Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa. |
| CA2589770A1 (en) * | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
| WO2006069381A2 (en) | 2004-12-22 | 2006-06-29 | Enterprise Integration Group | Turn-taking confidence |
| CA2604516A1 (en) | 2005-04-13 | 2006-10-19 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| US7923464B2 (en) | 2005-12-05 | 2011-04-12 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
| TWI391381B (zh) * | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
-
2007
- 2007-02-27 TW TW096106596A patent/TWI391381B/zh not_active IP Right Cessation
- 2007-03-22 ES ES07727240T patent/ES2355163T3/es active Active
- 2007-03-22 WO PCT/EP2007/052766 patent/WO2007110374A1/en not_active Ceased
- 2007-03-22 SI SI200730455T patent/SI2001855T1/sl unknown
- 2007-03-22 AU AU2007229502A patent/AU2007229502B2/en not_active Ceased
- 2007-03-22 US US12/279,511 patent/US7902230B2/en active Active
- 2007-03-22 AT AT07727240T patent/ATE486856T1/de active
- 2007-03-22 NZ NZ569438A patent/NZ569438A/en not_active IP Right Cessation
- 2007-03-22 CN CN2007800059554A patent/CN101384559B/zh not_active Expired - Fee Related
- 2007-03-22 BR BRPI0710203-8A patent/BRPI0710203A2/pt not_active IP Right Cessation
- 2007-03-22 KR KR1020087026085A patent/KR20080111097A/ko not_active Ceased
- 2007-03-22 MX MX2008010885A patent/MX2008010885A/es active IP Right Grant
- 2007-03-22 CA CA002647252A patent/CA2647252A1/en not_active Abandoned
- 2007-03-22 PL PL07727240T patent/PL2001855T3/pl unknown
- 2007-03-22 MY MYPI20082972A patent/MY149855A/en unknown
- 2007-03-22 DE DE602007010261T patent/DE602007010261D1/de active Active
- 2007-03-22 JP JP2009500873A patent/JP5260489B2/ja not_active Expired - Fee Related
- 2007-03-22 HR HR20100616T patent/HRP20100616T1/hr unknown
- 2007-03-22 RU RU2008129868/04A patent/RU2435759C2/ru not_active IP Right Cessation
- 2007-03-22 PT PT07727240T patent/PT2001855E/pt unknown
- 2007-03-22 DK DK07727240.9T patent/DK2001855T3/da active
- 2007-03-22 EP EP10182058A patent/EP2319837B1/en active Active
- 2007-03-22 EP EP07727240A patent/EP2001855B1/en not_active Not-in-force
- 2007-03-23 AR ARP070101206A patent/AR060084A1/es unknown
-
2008
- 2008-06-19 IL IL192297A patent/IL192297A/en not_active IP Right Cessation
- 2008-10-23 NO NO20084481A patent/NO20084481L/no not_active Application Discontinuation
-
2010
- 2010-12-09 CY CY20101101143T patent/CY1111603T1/el unknown
-
2011
- 2011-01-20 US US13/009,988 patent/US8288418B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vay et al. | The thermo‐TRP ion channel family: properties and therapeutic implications | |
| Romeo-Guitart et al. | Neuroprotective drug for nerve trauma revealed using artificial intelligence | |
| Iniaghe et al. | Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage | |
| Chen et al. | Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway | |
| Tang et al. | FGF2 attenuates neural cell death via suppressing autophagy after rat mild traumatic brain injury | |
| EP2943222B1 (en) | Solid solution compositions and use in severe pain | |
| Gao et al. | Dexmedetomidine protects hippocampal neurons against hypoxia/reoxygenation-induced apoptosis through activation HIF-1α/p53 signaling | |
| Li et al. | Surgery-induced hippocampal angiotensin II elevation causes blood-brain barrier disruption via MMP/TIMP in aged rats | |
| Kumar et al. | Pharmacology of Src family kinases and therapeutic implications of their modulators | |
| Chang et al. | Heat shock protein 70 protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus via inhibition of nuclear factor-κB activation-induced nitric oxide synthase II expression | |
| BRPI0909945A2 (pt) | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" | |
| EA024147B1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| Aghajanpour et al. | Tramadol: a potential neurotoxic agent affecting prefrontal cortices in adult male rats and PC-12 cell line | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| IL268125B2 (en) | Pridopidine for the treatment of fragile x syndrome | |
| WO2007008548A2 (en) | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | |
| Lan et al. | Berberine attenuates high glucose-induced proliferation and extracellular matrix accumulation in mesangial cells: involvement of suppression of cell cycle progression and NF-κB/AP-1 pathways | |
| KR20210010955A (ko) | 정신분열병의 음성 증상을 치료하기 위한 트랜스-4-[2-[4-(2,3-디클로로페닐)-피페라진-1-일]-에틸]-n,n-디메틸카바모일-사이클로헥실아민 | |
| Zhang et al. | STING-mediated neuroinflammation: a therapeutic target in neurodegenerative diseases | |
| Lee et al. | Umbelliferone modulates depression-like symptoms by altering monoamines in a rat post-traumatic stress disorder model | |
| Zheng et al. | Brain edema and protein expression of c-Fos and c-Jun in the brain after diffused brain injury | |
| Akan et al. | The effects of carvacrol on transient receptor potential (TRP) channels in an animal model of Parkinson’s disease | |
| Lv et al. | Luteolin prevents LPS-induced TNF-α expression in cardiac myocytes through inhibiting NF-κB signaling pathway | |
| Tiwari et al. | Lysophosphatidic acid receptor 1 plays a pathogenic role in permanent brain ischemic stroke by modulating neuroinflammatory responses | |
| Hadwen et al. | VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models |